Kidney TransplantationPhase 2NCT00106639
A 6-Month Study Of CP-690,550 Versus Tacrolimus In Kidney Transplant Patients
A Phase 2 study testing CP-690,550 and tacrolimus in people with Kidney Transplantation, run by Pfizer at 20 sites in United States.
Trial summary
This Phase 2 study was designed to evaluate the safety and efficacy of 2 dose levels of CP-690,550 (15 mg twice daily and 30 mg twice) against tacrolimus, in combination with basiliximab induction, mycophenolate mofetil and corticosteroids, in kidney transplant patients. Read more about this study
- Who is it for?
- Ages 18 to 70 years
- Conditions the study is for
- Kidney Transplantation
- What is being tested?
- CP-690,550 and tacrolimus
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 61 participants
- Where
- 20 sitesUnited States
- Study dates
- May 2005to Jul 2006
- Phase
- Phase 2
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 70 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Recipient of a first-time kidney transplant
- Between the ages of 18 and 70 years, inclusive
Who cannot join
- Recipient of any non-kidney transplant
Trial locations and contacts
20 sites in 1 country.
20 sites in 1 country
United States20 sites
Pfizer Investigational Site
Chicago, Illinois, 60611
Pfizer Investigational Site
Dallas, Texas, 75204
Pfizer Investigational Site
Dallas, Texas, 75246
Pfizer Investigational Site
Denver, Colorado, 80262
Pfizer Investigational Site
Livingston, New Jersey, 07039
Pfizer Investigational Site
Los Angeles, California, 90057
Pfizer Investigational Site
Los Angeles, California, 92356
Pfizer Investigational Site
Milwaukee, Wisconsin, 53226
Pfizer Investigational Site
New Orleans, Louisiana, 70112
Pfizer Investigational Site
New York, New York, 10021
Pfizer Investigational Site
New York, New York, 10029
Pfizer Investigational Site
Palo Alto, California, 94304
Pfizer Investigational Site
Portland, Oregon, 97210
Pfizer Investigational Site
Richmond, Virginia, 23298
Pfizer Investigational Site
San Diego, California, 92123
Pfizer Investigational Site
San Francisco, California, 94115
Pfizer Investigational Site
San Francisco, California, 94143-0780
Pfizer Investigational Site
St Louis, Missouri, 63110-1092
Pfizer Investigational Site
St Louis, Missouri, 63110
Pfizer Investigational Site
Stanford, California, 94305
About this study
Official title: A 6-Month, Phase 2, Multicenter, Randomized, Open-Label, Comparative Study Of 2 Dose Levels Of CP-690,550 Administered Concomitantly With IL-2 Receptor Antagonist Induction Therapy, Mycophenolate Mofetil And Corticosteroids Versus A Tacrolimus-Based Immunosuppressive Regimen For The Prevention Of Allograft Rejection In De Novo Renal Allograft Recipients
This Phase 2 study was designed to evaluate the safety and efficacy of 2 dose levels of CP-690,550 (15 mg twice daily and 30 mg twice) against tacrolimus, in combination with basiliximab induction, mycophenolate mofetil and corticosteroids, in kidney transplant patients. Stage 1 was to randomize approximately 54 subjects. After all Stage 1 subjects had completed 6 months of treatment, Stage 2 was to randomize an additional 195 subjects to the same treatment groups.
- Conditions
- Kidney Transplantation
- Being tested
- CP-690,550, tacrolimus
- Keywords
- tofacitinib, CP-690550, kidney transplant
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
CP-690,550Drug
15 mg twice daily
CP-690,550Drug
30 mg twice daily
tacrolimusDrug
dose adjusted according to level
| Study group | Role | What they receive |
|---|---|---|
| CP-690,550 15 mg BID | Experimental | Not described Receives: Drug: CP-690,550 |
| CP-690,550 30 mg BID | Experimental | Not described Receives: Drug: CP-690,550 |
| tacrolimus | Active comparator | Not described Receives: Drug: tacrolimus |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of Participants With First Biopsy Proven Acute Rejection (BPAR) at Month 6
BPAR categorized as acute rejection as interpreted by the central blinded pathologist according to the Banff 97 working classification.
Measured: Baseline up to Month 6
Glomerular Filtration Rate (GFR) by Nankivell Equation at Month 6
GFR: index of kidney function described the flow rate of filtered fluid through the kidney. GFR was measured directly or estimated using established formulas. GFR was calculated by creatinine clearance (CLcr) using Nankivell equation. CLcr by Nankivell equation= (6.7 per serum creatinine) plus (0.25*body weight) minus (0.5*serum urea) minus (100 per square height) plus (35 for male/25 for female). A normal GFR is >90 milliliter/minute (mL/min), although children and older people usually have a lower GFR. Lower values indicated poor kidney function. A GFR <15 mL/min indicated kidney failure.
Measured: Month 6
Secondary outcomes (39)
Number of Participants With Treatment Failure
Treatment failure was defined as the first occurrence of BPAR, graft loss, participant's death or premature discontinuation of study medication for any reason.
Measured: Month 3, 6
Number of Participants With First Biopsy Proven Acute Rejection (BPAR) at Month 3
BPAR categorized as acute rejection as interpreted by the central blinded pathologist according to the Banff 97 working classification.
Measured: Baseline up to Month 3
Number of Participants With First Biopsy Proven Chronic Allograft Nephropathy (BPCAN)
BPCAN categorized as chronic allograft nephropathy as interpreted by the central blinded pathologist according to the Banff 97 working classification.
Measured: Month 3, 6
Number of Participants With Ordered Categorical Severity of First Biopsy Proven Acute Rejection (BPAR)
Ordered categorical severity of first BPAR was classified according to the Banff Classification. Grade IA: moderate tubulitis, grade IB: severe tubulitis, grade IIA: mild to moderate intimal arteritis, grade IIB: severe intimal arteritis, grade III: transmural arteritis. (Racusen et al: The Banff classification, 1999).
Measured: Month 3, 6
Number of Participants With Ordered Categorical Severity of First Biopsy Proven Chronic Allograft Nephropathy (BPCAN)
Ordered categorical severity of first BPCAN was classified according to the Banff Classification. Grade I: mild, grade II: moderate and grade III: severe interstitial fibrosis and tubular atrophy/loss. (Racusen et al: The Banff classification, 1999).
Measured: Month 3, 6
Number of Participants With Efficacy Failure
Efficacy failure was the first occurrence of BPAR, graft loss or participant's death.
Measured: Month 3, 6
Number of Participants With Graft Loss
Graft loss was defined as graft nephrectomy, participant's death due to graft loss, re-transplantation, or return to dialysis for greater than or equal to (>=) 6 consecutive weeks.
Measured: Month 6
Number of Participants Who Died
Measured: Month 6
Number of Participants With Rejection
Rejection was defined as first occurrence of BPAR, antibody mediated rejection, or suspicious for acute rejection.
Measured: Month 3, 6
Population Pharmacokinetics (PK)
Data for this Outcome Measure are not reported here because the analysis population includes participants who were not enrolled in this study. ClinicalTrials.gov is designed for reporting results from only those participants who were enrolled in the study and described in the Participant Flow and Baseline Characteristics modules.
Measured: Pre-dose on Day 1, 3, 7, 14, Month 1, 3, 6, between 1 to 2 hours post-dose at Month 3 and between 3 to 4 hours post-dose at Month 6
Fluorescence-Activated Cell Sorting (FACS) of Lymphocyte Subsets
The absolute cell counts of cluster of differentiation 8 (CD8): Cytotoxic T-lymphocytes reactive with major histocompatibility complex-1 (MHC-I), CD19: B- Lymphocytes, CD56: natural killer cells were determined using FACS, a specialized type of flow cytometry which sorts a heterogeneous mixture based upon the specific light scattering and fluorescent characteristics of each cell.
Measured: Baseline, Day 14, Month 1, 3, 6
Reticulocyte Count
Reticulocytes are slightly immature red blood cells in the blood. Reticulocyte counts are reported as cells*10^3 per cubic millimeter (cells*10^3/mm^3).
Measured: Baseline, Day 14, Month 1, 3, 6
Trough Levels of Tacrolimus (TAC)
Measured: Pre-dose on Day 14, Month 1, 3, 6
36-Item Short-Form Health Survey (SF-36) Version 2.0 (V2)
SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. These 8 aspects can also be summarized as physical and mental component scores (CS). Total of 11 variables were analyzed (8 subscales, 2 composite subscales and Question 2 "how would you rate your health in general now?" (range 1= better, 5= worst). The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).
Measured: Baseline, Month 6
End-Stage Renal Disease Symptom Checklist-Transplantation Module (ESRD-SCL)
ESRD-SCL:43-item disease specific self-administered questionnaire. Participants' rated question"At the moment,how much do you suffer?"for each item on 5 point scale,ranged (Ra) 0(not at all)to 4(extremely).Consisted of 6 subscales:cardiac and renal dysfunction;Ra 0-28,increased(In) growth of gum and hair;Ra 0-20,limited cognitive capacity;Ra 0-32,limited physical capacity;Ra 0-40,side effects (SEs) of corticosteroids;Ra 0-20,transplantation associated psychological distress(TAPD);Ra 0-32(higher scores=greater dysfunction for each subscale).Total score:0-172,higher scores=greater dysfunction.
Measured: Baseline, Month 6
Healthcare Resource Utilization Questionnaire (HCRUQ)
Healthcare Resource Utilization Questionnaire (HCRUQ) was used to assess healthcare resources which included number of events such as physician and other health professional visits, number of treatments or diagnostic tests, number of hospitalizations, and number of emergency room visits.
Measured: Baseline, Month 6
Healthcare Resource Utilization Questionnaire (HCRUQ) - 5th Question
Fifth question in the HCRUQ was "Upon discharge from the hospital, did you return to your previous place of residence?" and number of participants who responded "yes or no" to the question was reported.
Measured: Month 6
Glomerular Filtration Rate (GFR) by Cockcroft-Gault
GFR: index of kidney function described the flow rate of filtered fluid through the kidney. GFR was measured directly or estimated using established formulas. GFR was calculated using Cockcroft-Gault equation. GFR by Cockcroft-Gault equation= body weight*(140 minus age in years) divided by (72*serum creatinine). For females, value obtained was multiplied by 0.85. A normal GFR is >90 mL/min, although children and older people usually have a lower GFR. Lower values indicated poor kidney function. A GFR <15 mL/min indicated kidney failure.
Measured: Day 14, Month 1, 3, 6
Glomerular Filtration Rate (GFR) by Modification of Diet in Renal Disease (MDRD) Equation
GFR: index of kidney function described the flow rate of filtered fluid through the kidney. GFR was measured directly or estimated using established formulas. GFR was calculated using MDRD equation. GFR by MDRD equation= 170 * (serum creatinine) ^ (-0.999)*(age in years)^(-0.176)*(0.762 if female) * (1.18 if black)*(blood urea nitrogen concentration)^(-0.170)*(serum albumin concentration)^(0.318). Normal GFR is >90 mL/min/1.73 square meter (m^2), although children and older people usually have a lower GFR. Lower values indicated poor kidney function. A GFR <15 mL/min indicated kidney failure.
Measured: Day 14, Month 1, 3, 6
Glomerular Filtration Rate (GFR) by Reciprocal of Serum Creatinine (1/sCr)
GFR is a measure of renal function. The reciprocal of serum creatinine is an estimate of GFR.
Measured: Day 14, Month 1, 3, 6
Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 2 months after last dose that were absent before treatment or that worsened relative to pretreatment state.
Measured: Baseline up to Month 8 (2 months follow-up)
Number of Participants With First Clinically Significant Infection
Clinically significant (Viral, Bacterial and Fungal) infection was defined as the presence of presumed or documented infection confirmed by culture, biopsy, genomic or serologic findings post-randomization and required hospitalization or anti-infective treatment, or otherwise deemed significant by the Investigator.
Measured: Month 3, 6
Number of Participants With New Onset Diabetes Mellitus (NODM)
Measured: Month 3, 6
Fasting Serum Glucose Levels
Measured: Baseline, Day 14, Month 1, 3, 6
Number of Participants With Hypercholesterolemia
Hypercholesterolemia is a condition characterized by very high levels of cholesterol in the blood. Hypercholesterolemia was defined as a value of total serum cholesterol greater than 240 mg/dL.
Measured: Baseline, Day 14, Month 1, 3, 6
Total Serum Cholesterol, Low Density Lipoprotein (LDL) and High Density Lipoprotein (HDL) Levels
Measured: Baseline, Day 14, Month 1, 3, 6
Number of Participants With Hypertriglyceridemia
Hypertriglyceridemia was defined as a value of triglycerides greater than 200 mg/dL.
Measured: Baseline, Day 14, Month 1, 3, 6
Supine Systolic and Diastolic Blood Pressure (BP)
Measured: Baseline, Day 2, 3, 14, Month 1, 3, 6
Number of Participants With Drug Usage
Lipid lowering agents, antihypertensive agents, oral hypoglycemic agents (OHA) , anti-diabetic agents (ADA) and insulin drug usage was collected.
Measured: Baseline, Day 14, Month 1, 3, 6
Epstein Barr Virus (EBV) and Cytomegalovirus (CMV) Deoxyribonucleic Acid (DNA) Load
Measured: Baseline, Month 1, 3, 6 for CMV; Baseline, Day 14, Month 1, 3, 6 for EBV
BK Virus (BKV) Deoxyribonucleic Acid (DNA) Load
Measured: Baseline, Month 1, 3, 6
Number of Participants With Cytomegalovirus (CMV) Disease
Measured: Month 3, 6
Total White Blood Cells (WBC), Absolute Basophil, Absolute Eosinophil, Absolute Lymphocyte, Absolute Monocyte, Absolute Neutrophil
Measured: Baseline, Day 14, Month 1, 3, 6
Absolute Platelet Levels
Measured: Baseline, Day 14, Month 1, 3, 6
Hemoglobin Level
Hemoglobin is the protein molecule in red blood cells that carries oxygen from the lungs to the body's tissues and returns carbon dioxide from the tissues back to the lungs.
Measured: Baseline, Day 14, Month 1, 3, 6
Hematocrit Level
The hematocrit is recorded as the percentage of volume of red blood cells (RBCs) in a blood sample.
Measured: Baseline, Day 14, Month 1, 3, 6
Alanine Aminotransferase (ALT) Level
ALT is the enzyme found in the liver and it is measured to see if the liver is damaged or diseased.
Measured: Baseline, Day 14, Month 1, 3, 6
Electrocardiogram (ECG) Parameters
ECG parameters included PR interval, QT interval, corrected QT using Bazett's formula (QTcB) and QTc using Fridericia's formula (QTcF) interval, and QRS width.
Measured: Baseline, Month 3, 6
Number of Participants With Discontinuation
Measured: Month 1, 2, 3, 4, 5, 6
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Mar 2005 (estimated)
- Study startMay 2005
- Primary completionJul 2006
- Study completionJul 2006
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Kidney TransplantationStudies of the same condition, open and under way.
- More trials run by PfizerThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 61 participants (actual)
Sponsor and investigators
- Lead sponsor
- Pfizer
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Pfizer CT.gov Call Center, Study director, Pfizer
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00106639
- Sponsor's protocol ID
- A3921009
- Status last verified
- Feb 2013
- First submitted
- 28 Mar 2005
- Last updated
- 12 Mar 2013
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
Publications
Busque S, Leventhal J, Brennan DC, Steinberg S, Klintmalm G, Shah T, Mulgaonkar S, Bromberg JS, Vincenti F, Hariharan S, Slakey D, Peddi VR, Fisher RA, Lawendy N, Wang C, Chan G. Calcineurin-inhibitor-free immunosuppression based on the JAK inhibitor CP-690,550: a pilot study in de novo kidney allograft recipients. Am J Transplant. 2009 Aug;9(8):1936-45. doi: 10.1111/j.1600-6143.2009.02720.x.
PubMed 19660021
Study at a glance
From the registry record, last updated by the sponsor on 12 Mar 2013. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A 6-Month, Phase 2, Multicenter, Randomized, Open-Label, Comparative Study Of 2 Dose Levels Of CP-690,550 Administered Concomitantly With IL-2 Receptor Antagonist Induction Therapy, Mycophenolate Mofetil And Corticosteroids Versus A Tacrolimus-Based Immunosuppressive Regimen For The Prevention Of Allograft Rejection In De Novo Renal Allograft Recipients
- ClinicalTrials.gov ID
- NCT00106639
- Acronym / sponsor ID
- A3921009
- Conditions
- Kidney Transplantation
- Keywords
- tofacitinib, CP-690550, kidney transplant
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 61 participants (actual)
- Lead sponsor
- PfizerIndustry (pharma, biotech, devices)
- Study start
- May 2005
- Primary completion
- Jul 2006 (actual)
- Study completion
- Jul 2006 (actual)
- First posted
- 29 Mar 2005 (estimated)
- Results
- Posted 12 Mar 2013
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This Phase 2 study was designed to evaluate the safety and efficacy of 2 dose levels of CP-690,550 (15 mg twice daily and 30 mg twice) against tacrolimus, in combination with basiliximab induction, mycophenolate mofetil and corticosteroids, in kidney transplant patients. Stage 1 was to randomize approximately 54 subjects. After all Stage 1 subjects had completed 6 months of treatment, Stage 2 was to randomize an additional 195 subjects to the same treatment groups.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| CP-690,550 15 mg BID | Experimental | Drug: CP-690,550 |
| CP-690,550 30 mg BID | Experimental | Drug: CP-690,550 |
| tacrolimus | Active comparator | Drug: tacrolimus |
Who may qualify
- Ages
- 18 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- Recipient of a first-time kidney transplant
- Between the ages of 18 and 70 years, inclusive
Key exclusion criteria (1 listed)
- Recipient of any non-kidney transplant
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| CP-690,55015 mg twice daily | Drug | CP-690,550 15 mg BID |
| CP-690,55030 mg twice daily | Drug | CP-690,550 30 mg BID |
| tacrolimusdose adjusted according to level | Drug | tacrolimus |
Primary outcome
Number of Participants With First Biopsy Proven Acute Rejection (BPAR) at Month 6
Time frame: Baseline up to Month 6
BPAR categorized as acute rejection as interpreted by the central blinded pathologist according to the Banff 97 working classification.
Glomerular Filtration Rate (GFR) by Nankivell Equation at Month 6
Time frame: Month 6
GFR: index of kidney function described the flow rate of filtered fluid through the kidney. GFR was measured directly or estimated using established formulas. GFR was calculated by creatinine clearance (CLcr) using Nankivell equation. CLcr by Nankivell equation= (6.7 per serum creatinine) plus (0.25*body weight) minus (0.5*serum urea) minus (100 per square height) plus (35 for male/25 for female). A normal GFR is >90 milliliter/minute (mL/min), although children and older people usually have a lower GFR. Lower values indicated poor kidney function. A GFR <15 mL/min indicated kidney failure.
39 secondary outcomes
Number of Participants With Treatment Failure
Time frame: Month 3, 6
Number of Participants With First Biopsy Proven Acute Rejection (BPAR) at Month 3
Time frame: Baseline up to Month 3
Number of Participants With First Biopsy Proven Chronic Allograft Nephropathy (BPCAN)
Time frame: Month 3, 6
Number of Participants With Ordered Categorical Severity of First Biopsy Proven Acute Rejection (BPAR)
Time frame: Month 3, 6
Number of Participants With Ordered Categorical Severity of First Biopsy Proven Chronic Allograft Nephropathy (BPCAN)
Time frame: Month 3, 6
Number of Participants With Efficacy Failure
Time frame: Month 3, 6
Number of Participants With Graft Loss
Time frame: Month 6
Number of Participants Who Died
Time frame: Month 6
Number of Participants With Rejection
Time frame: Month 3, 6
Population Pharmacokinetics (PK)
Time frame: Pre-dose on Day 1, 3, 7, 14, Month 1, 3, 6, between 1 to 2 hours post-dose at Month 3 and between 3 to 4 hours post-dose at Month 6
Fluorescence-Activated Cell Sorting (FACS) of Lymphocyte Subsets
Time frame: Baseline, Day 14, Month 1, 3, 6
Reticulocyte Count
Time frame: Baseline, Day 14, Month 1, 3, 6
Trough Levels of Tacrolimus (TAC)
Time frame: Pre-dose on Day 14, Month 1, 3, 6
36-Item Short-Form Health Survey (SF-36) Version 2.0 (V2)
Time frame: Baseline, Month 6
End-Stage Renal Disease Symptom Checklist-Transplantation Module (ESRD-SCL)
Time frame: Baseline, Month 6
Healthcare Resource Utilization Questionnaire (HCRUQ)
Time frame: Baseline, Month 6
Healthcare Resource Utilization Questionnaire (HCRUQ) - 5th Question
Time frame: Month 6
Glomerular Filtration Rate (GFR) by Cockcroft-Gault
Time frame: Day 14, Month 1, 3, 6
Glomerular Filtration Rate (GFR) by Modification of Diet in Renal Disease (MDRD) Equation
Time frame: Day 14, Month 1, 3, 6
Glomerular Filtration Rate (GFR) by Reciprocal of Serum Creatinine (1/sCr)
Time frame: Day 14, Month 1, 3, 6
Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)
Time frame: Baseline up to Month 8 (2 months follow-up)
Number of Participants With First Clinically Significant Infection
Time frame: Month 3, 6
Number of Participants With New Onset Diabetes Mellitus (NODM)
Time frame: Month 3, 6
Fasting Serum Glucose Levels
Time frame: Baseline, Day 14, Month 1, 3, 6
Number of Participants With Hypercholesterolemia
Time frame: Baseline, Day 14, Month 1, 3, 6
Total Serum Cholesterol, Low Density Lipoprotein (LDL) and High Density Lipoprotein (HDL) Levels
Time frame: Baseline, Day 14, Month 1, 3, 6
Number of Participants With Hypertriglyceridemia
Time frame: Baseline, Day 14, Month 1, 3, 6
Supine Systolic and Diastolic Blood Pressure (BP)
Time frame: Baseline, Day 2, 3, 14, Month 1, 3, 6
Number of Participants With Drug Usage
Time frame: Baseline, Day 14, Month 1, 3, 6
Epstein Barr Virus (EBV) and Cytomegalovirus (CMV) Deoxyribonucleic Acid (DNA) Load
Time frame: Baseline, Month 1, 3, 6 for CMV; Baseline, Day 14, Month 1, 3, 6 for EBV
BK Virus (BKV) Deoxyribonucleic Acid (DNA) Load
Time frame: Baseline, Month 1, 3, 6
Number of Participants With Cytomegalovirus (CMV) Disease
Time frame: Month 3, 6
Total White Blood Cells (WBC), Absolute Basophil, Absolute Eosinophil, Absolute Lymphocyte, Absolute Monocyte, Absolute Neutrophil
Time frame: Baseline, Day 14, Month 1, 3, 6
Absolute Platelet Levels
Time frame: Baseline, Day 14, Month 1, 3, 6
Hemoglobin Level
Time frame: Baseline, Day 14, Month 1, 3, 6
Hematocrit Level
Time frame: Baseline, Day 14, Month 1, 3, 6
Alanine Aminotransferase (ALT) Level
Time frame: Baseline, Day 14, Month 1, 3, 6
Electrocardiogram (ECG) Parameters
Time frame: Baseline, Month 3, 6
Number of Participants With Discontinuation
Time frame: Month 1, 2, 3, 4, 5, 6
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Mar 2013.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 19660021Busque S, Leventhal J, Brennan DC, Steinberg S, Klintmalm G, Shah T, Mulgaonkar S, Bromberg JS, Vincenti F, Hariharan S, Slakey D, Peddi VR, Fisher RA, Lawendy N, Wang C, Chan G. Calcineurin-inhibitor-free immunosuppression based on the JAK inhibitor CP-690,550: a pilot study in de novo kidney allograft recipients. Am J Transplant. 2009 Aug;9(8):1936-45. doi: 10.1111/j.1600-6143.2009.02720.x.
- To obtain contact information for a study center near you, click here.Link provided by the sponsor.
Related trials for Kidney Transplantation
Enrolling by invitation
Online Exercise Program for Transplant Patients: A Pilot Study
Kidney Transplantation, Physical Function
RecruitingPhase 2
A Study of Mezagitamab in Adults With Late Antibody-Mediated Rejection (AMR) After a Kidney Transplant
Antibody-Mediated Rejection (AMR)
Not yet recruiting
Hypothermic Kidney Machine Perfusion With Omnisol
End Stage Renal Disease (ESRD), Kidney Transplant
Not yet recruitingEarly Phase 1
Biomarker-Guided Mycophenolate Mofetil Elimination in Low-Risk Older Adult Kidney Transplant Recipients
Kidney Transplant Recipient
Recruiting
Non-Invasive Monitoring of Pediatric Kidney Transplant Recipients and Immunosuppression Personalization: an Open-labeled Multicenter Randomized Controlled Study
Pediatric Kidney Disease, Transplant;Failure,Kidney
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Pfizer CT.gov Call Center study director
Pfizer
20 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing CP-690,550 and tacrolimus in people with Kidney Transplantation, run by Pfizer at 20 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 12 Mar 2013. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 20 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 12 Mar 2013). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of Participants With First Biopsy Proven Acute Rejection (BPAR) at Month 6 (time frame: Baseline up to Month 6). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00106639, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Mar 2013.